CN102370638A - 3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 - Google Patents
3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 Download PDFInfo
- Publication number
- CN102370638A CN102370638A CN2010102585454A CN201010258545A CN102370638A CN 102370638 A CN102370638 A CN 102370638A CN 2010102585454 A CN2010102585454 A CN 2010102585454A CN 201010258545 A CN201010258545 A CN 201010258545A CN 102370638 A CN102370638 A CN 102370638A
- Authority
- CN
- China
- Prior art keywords
- indole
- carbinol
- methyl hydride
- derivant
- indole methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 208000019423 liver disease Diseases 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 3
- VFTRKSBEFQDZKX-UHFFFAOYSA-N 3,3'-diindolylmethane Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4NC=3)=CNC2=C1 VFTRKSBEFQDZKX-UHFFFAOYSA-N 0.000 title abstract 9
- 229940093768 3,3'-diindolylmethane Drugs 0.000 title 1
- 235000010045 3,3'-diindolylmethane Nutrition 0.000 title 1
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 claims abstract description 206
- 235000002279 indole-3-carbinol Nutrition 0.000 claims abstract description 107
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 25
- 208000006454 hepatitis Diseases 0.000 claims abstract description 18
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 18
- 239000002243 precursor Substances 0.000 claims abstract description 14
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 claims abstract 13
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 121
- 241001597008 Nomeidae Species 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 31
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- 239000000460 chlorine Substances 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 150000001721 carbon Chemical group 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 10
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 201000008865 drug-induced hepatitis Diseases 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 150000003254 radicals Chemical class 0.000 abstract description 9
- 102000008186 Collagen Human genes 0.000 abstract description 5
- 108010035532 Collagen Proteins 0.000 abstract description 5
- 229920001436 collagen Polymers 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 206010016654 Fibrosis Diseases 0.000 abstract description 2
- 230000004761 fibrosis Effects 0.000 abstract description 2
- TWJAXIHBWPVMIR-UHFFFAOYSA-N diindolylmethane Natural products C1=CC=C2NC(CC=3NC4=CC=CC=C4C=3)=CC2=C1 TWJAXIHBWPVMIR-UHFFFAOYSA-N 0.000 abstract 3
- 230000020411 cell activation Effects 0.000 abstract 1
- 210000004500 stellate cell Anatomy 0.000 abstract 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 33
- XGDLHLISLBPXPR-UHFFFAOYSA-N C.C1=CC=C2NC=CC2=C1.C1=CC=C2NC=CC2=C1 Chemical compound C.C1=CC=C2NC=CC2=C1.C1=CC=C2NC=CC2=C1 XGDLHLISLBPXPR-UHFFFAOYSA-N 0.000 description 23
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 21
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 19
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- DUSHSPLKAUXPEY-UHFFFAOYSA-N (5-chloro-1h-indol-3-yl)methanol Chemical compound C1=C(Cl)C=C2C(CO)=CNC2=C1 DUSHSPLKAUXPEY-UHFFFAOYSA-N 0.000 description 16
- JYWPLBCRBPLXBG-UHFFFAOYSA-N [N+](=O)([O-])C=1C=C2C(CNC2=CC1)CO Chemical compound [N+](=O)([O-])C=1C=C2C(CNC2=CC1)CO JYWPLBCRBPLXBG-UHFFFAOYSA-N 0.000 description 16
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 14
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 14
- 229960002591 hydroxyproline Drugs 0.000 description 14
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000034994 death Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 210000000582 semen Anatomy 0.000 description 10
- 230000003442 weekly effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 206010019692 hepatic necrosis Diseases 0.000 description 6
- 230000007866 hepatic necrosis Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000013246 thioacetic acid model Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- WHOOUMGHGSPMGR-UHFFFAOYSA-N indol-3-ylacetaldehyde Chemical class C1=CC=C2C(CC=O)=CNC2=C1 WHOOUMGHGSPMGR-UHFFFAOYSA-N 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- -1 5-methoxyl group Chemical class 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- BZCGWAXQDLXLQM-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O.ClP(Cl)(Cl)=O BZCGWAXQDLXLQM-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical group C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000013245 carbon tetrachloride model Methods 0.000 description 1
- DQWSOBBQMZKSBU-KHNSGPGUSA-N chembl2110293 Chemical compound O([C@@H](C(C1Cl)O)O[C@H]2C(O)C([C@H](O[C@@H]3C(COP(O)=O)O[C@@H](C(C3Cl)O)O[C@@H]3C(COP(O)=O)O[C@@H](C(C3Cl)O)O[C@@H]3C(COP(O)=O)O[C@@H](C(C3Cl)O)O[C@@H]3C(COP(O)=O)O[C@@H](C(C3OP(O)=O)O)O3)OC2COP(O)=O)O)C(COP(O)=O)[C@H]1O[C@@H]1C(O)C(Cl)[C@H]3C(COP(O)=O)O1 DQWSOBBQMZKSBU-KHNSGPGUSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009267 minimal disease activity Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 羟脯氨酸(μg/g liver) | 谷丙转氨酶(U/mg protein) |
模型组 | 356±43 | 372±24 |
I3C | 237±11* | 245±32* |
DIM | 176±21* | 204±37* |
5-Cl-I3C | 220±35* | 250±23* |
5,5’-Cl-DIM | 177±28* | 182±13* |
2-C5-I3C | 266±44* | 298±37* |
2,2’-C5-DIM | 191±30* | 205±27* |
5-NO-I3C | 217±12* | 220±17* |
5,5’-NO-DIM | 146±19* | 162±29* |
N-MOE-I3C | 189±23* | 200±16* |
N,N’-MOE-DIM | 163±19* | 190±21* |
组别 | 羟脯氨酸(μg/g liver) | 谷丙转氨酶(U/mg protein) |
模型组 | 366±33 | 384±42 |
I3C | 216±12* | 221±22* |
DIM | 136±24* | 134±27* |
5-Cl-I3C | 213±24* | 230±31* |
5,5’-Cl-DIM | 167±16* | 172±24* |
2-C5-I3C | 246±42* | 268±28* |
2,2’-C5-DIM | 172±33* | 189±17* |
5-NO-I3C | 205±22* | 200±23* |
5,5’-NO-DIM | 136±29* | 142±18* |
N-MOE-I3C | 169±32* | 187±26* |
N,N’-MOE-DIM | 153±25* | 171±11* |
Claims (8)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102585454A CN102370638B (zh) | 2010-08-20 | 2010-08-20 | 3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 |
PCT/CN2010/080348 WO2012022101A1 (zh) | 2010-08-20 | 2010-12-28 | 二吲哚甲烷及前体和衍生物在制备治疗肝病药物中的应用 |
JP2013524335A JP5759000B2 (ja) | 2010-08-20 | 2010-12-28 | 肝疾患治療の薬物の製造におけるジインドリルメタン及びその前駆体並びにその誘導体の応用 |
EP10856099.6A EP2606887B1 (en) | 2010-08-20 | 2010-12-28 | Diindolylmethane, precursor and derivatives thereof in preparation of medicaments for treating liver diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102585454A CN102370638B (zh) | 2010-08-20 | 2010-08-20 | 3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102370638A true CN102370638A (zh) | 2012-03-14 |
CN102370638B CN102370638B (zh) | 2013-10-23 |
Family
ID=45604715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102585454A Active CN102370638B (zh) | 2010-08-20 | 2010-08-20 | 3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2606887B1 (zh) |
JP (1) | JP5759000B2 (zh) |
CN (1) | CN102370638B (zh) |
WO (1) | WO2012022101A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105853409A (zh) * | 2016-06-18 | 2016-08-17 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗器官移植排斥反应药物中的应用 |
CN105853410A (zh) * | 2016-06-18 | 2016-08-17 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗脂溢性脱发药物中的应用 |
CN105963294A (zh) * | 2016-06-18 | 2016-09-28 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗红斑狼疮药物中的应用 |
CN105963295A (zh) * | 2016-06-18 | 2016-09-28 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗强直性脊柱炎物中的应用 |
CN108245509A (zh) * | 2018-01-29 | 2018-07-06 | 南京大学 | Dim及其衍生物在制备防治化疗引发损伤药物中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2537025C1 (ru) * | 2013-05-28 | 2014-12-27 | Всеволод Иванович Киселев | Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций |
RU2740377C1 (ru) * | 2020-03-18 | 2021-01-13 | Всеволод Иванович Киселёв | Способ лечения эндометриоза и сопутствующего спаечного процесса лекарственным средством на основе 3,3'-дииндолилметана в комплексе с B-циклодекстрином |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1794986A (zh) * | 2003-03-27 | 2006-06-28 | 兰肯瑙医学研究所 | 治疗癌症的新方法 |
KR20090042689A (ko) * | 2007-10-27 | 2009-04-30 | 한림대학교 산학협력단 | 3,3’-디인돌릴메탄을 유효성분으로 함유하는 염증 질환의예방 및 치료용 조성물 |
CN101428016A (zh) * | 2008-12-23 | 2009-05-13 | 南京大学 | 二吲哚甲烷及其衍生物在类风湿关节炎治疗中的应用 |
KR20100070664A (ko) * | 2008-12-18 | 2010-06-28 | 연세대학교 산학협력단 | 인돌-3-카비놀 유도체를 유효성분으로 포함하는 비만, 고지혈증, 지방간 또는 당뇨의 예방 또는 치료용 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006521377A (ja) * | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ido阻害剤とその使用方法 |
US20060111423A1 (en) * | 2004-10-26 | 2006-05-25 | Zeligs Michael A | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease |
-
2010
- 2010-08-20 CN CN2010102585454A patent/CN102370638B/zh active Active
- 2010-12-28 EP EP10856099.6A patent/EP2606887B1/en active Active
- 2010-12-28 WO PCT/CN2010/080348 patent/WO2012022101A1/zh active Application Filing
- 2010-12-28 JP JP2013524335A patent/JP5759000B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1794986A (zh) * | 2003-03-27 | 2006-06-28 | 兰肯瑙医学研究所 | 治疗癌症的新方法 |
KR20090042689A (ko) * | 2007-10-27 | 2009-04-30 | 한림대학교 산학협력단 | 3,3’-디인돌릴메탄을 유효성분으로 함유하는 염증 질환의예방 및 치료용 조성물 |
KR20100070664A (ko) * | 2008-12-18 | 2010-06-28 | 연세대학교 산학협력단 | 인돌-3-카비놀 유도체를 유효성분으로 포함하는 비만, 고지혈증, 지방간 또는 당뇨의 예방 또는 치료용 조성물 |
CN101428016A (zh) * | 2008-12-23 | 2009-05-13 | 南京大学 | 二吲哚甲烷及其衍生物在类风湿关节炎治疗中的应用 |
Non-Patent Citations (3)
Title |
---|
PING JIE,ET AL: "Effect of indole-3-carbinol on activation,proliferation and collagen secretion of rat hepatic stellate cells", 《中国药理学与毒理学杂志》 * |
张春等: "吲哚-3-原醇对乙醇损伤性大鼠肝切片的保护作用", 《中国药理学通报》 * |
武晓茜等: "吲哚-3-原醇对乙醛所致精密肝切片中星状细胞活化的影响", 《中国药理学通报》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105853409A (zh) * | 2016-06-18 | 2016-08-17 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗器官移植排斥反应药物中的应用 |
CN105853410A (zh) * | 2016-06-18 | 2016-08-17 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗脂溢性脱发药物中的应用 |
CN105963294A (zh) * | 2016-06-18 | 2016-09-28 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗红斑狼疮药物中的应用 |
CN105963295A (zh) * | 2016-06-18 | 2016-09-28 | 张阳康 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗强直性脊柱炎物中的应用 |
CN108245509A (zh) * | 2018-01-29 | 2018-07-06 | 南京大学 | Dim及其衍生物在制备防治化疗引发损伤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2606887A4 (en) | 2014-04-30 |
JP5759000B2 (ja) | 2015-08-05 |
WO2012022101A1 (zh) | 2012-02-23 |
EP2606887A1 (en) | 2013-06-26 |
JP2013534225A (ja) | 2013-09-02 |
CN102370638B (zh) | 2013-10-23 |
EP2606887B1 (en) | 2018-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102370638B (zh) | 3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 | |
CN101940568B (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗蒽环抗癌药引起的心脏衰竭药物中的应用 | |
JP5294509B2 (ja) | シクロアストラゲノールモノグルコシド、その製造方法及び医薬用組成物としての使用 | |
CN102389419A (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治动脉粥样硬化药物中的应用 | |
CN100451023C (zh) | 左旋奥硝唑磷酸酯及其制备方法和用途 | |
CN102675199B (zh) | 一种蛋白质络氨酸磷酸酶抑制剂、其制备方法及其用途 | |
WO2006110299A1 (en) | 3,3'-diindolylmethane compositions inhibit angiogenesis | |
CN102335168B (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用 | |
CN1947796B (zh) | 化学修饰的阿德福韦或泰诺福韦 | |
Akamatsu et al. | Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E1 using lactosylated poly (L-glutamic hydrazide) as a carrier | |
CN105412011A (zh) | 一种载体本身具有抗肿瘤和抗转移活性的两亲性胶束 | |
CN106631957A (zh) | 一种靶向FAP‑alpha酶的抗肿瘤化合物及其制备方法与应用 | |
CN101279967B (zh) | 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途 | |
CN102327262A (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗糖尿病药物中的应用 | |
CN101229167B (zh) | 药物左亚叶酸钠的制备方法和在制备治疗肿瘤药物中的应用 | |
CN100537593C (zh) | 甘草酸复盐及其制剂 | |
CN100999500A (zh) | 奥硝唑的前体药物及其制备方法和用途 | |
CN101288651A (zh) | 一种复方甘草酸苷分散片剂及其制备方法 | |
CN102429901B (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肾纤维化药物中的应用 | |
CN102526012B (zh) | 视黄酸及其衍生物在制备治疗肝纤维化药物中的应用 | |
CN102389420A (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肺纤维化药物中的应用 | |
CN100560572C (zh) | 甘氨双唑酸的碱性氨基酸盐及其制备和用途 | |
US20210212966A1 (en) | Prodrug for therapeutic applications | |
CN102406641A (zh) | 索拉非尼在治疗纤维化病中的应用 | |
CN104922113A (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗胃溃疡药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180222 Address after: No. 8, Ningguo City Economic and Technological Development Zone, Xuancheng, Anhui Province Patentee after: NINGGUO WUYUE MEDICAL TECHNOLOGY CO.,LTD. Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231109 Address after: 230601 First Floor, Building 2-A, Furong Road North, Economic and Technological Development Zone, Hefei City, Anhui Province Patentee after: HEFEI DAMI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: No. 8 Chuangye Road, Ningguo Economic and Technological Development Zone, Xuancheng City, Anhui Province, 242300 Patentee before: NINGGUO WUYUE MEDICAL TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231218 Address after: No. 88 Dong'an Road, Anzhen Street, Xishan District, Wuxi City, Jiangsu Province, 214104 Patentee after: Wuxi Kanghe Qingyuan Biotechnology Co.,Ltd. Address before: 230601 First Floor, Building 2-A, Furong Road North, Economic and Technological Development Zone, Hefei City, Anhui Province Patentee before: HEFEI DAMI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |